Renovaro BioSciences Inc. | Corporate Overview

Overview

Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine

The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discovery

AI technology products projected to be in marketplace in 2024
Phase 1/2 human studies of pancreatic cancer and other solid tumors with poor longevity projected to begin second half of 2024

Read more

Overview

Latest News

View all news

Latest Presentation

Contact Us

For investor inquiries, please email us at:

ir@renovarobio.com

Quick Links

SEC Filings
Investor FAQs
Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Renovaro BioSciences Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Renovaro BioSciences Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options

Investor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote
Events & Presentations

Unsubscribe

Email Alert Sign Up Confirmation

Privacy Policy
Site Map